Juq 395 Hot! Direct

| Year | Milestone | Key Players | |------|-----------|-------------| | | High‑throughput screen of a 150 k compound library for inhibitors of the MurA enzyme (first step of peptidoglycan synthesis). | Dr. Lena Hoffmann, University of Munich (U‑M); JuqBio’s discovery team | | 2020 | Hit validation: compound #395 showed > 95 % inhibition of MurA in vitro with low cytotoxicity. | JuqBio R&D | | 2021 | Lead optimization: structural analogues synthesized, yielding Juq‑395 (C₁₈H₂₁N₅O₃·HCl). Improved potency (IC₅₀ = 12 nM) and pharmacokinetics. | JuqBio medicinal chemistry group | | 2022 | Patent granted (US 11,473,021 B2). First in‑vivo efficacy demonstrated in a murine thigh infection model against Staphylococcus aureus (including MRSA). | JuqBio pre‑clinical team | | 2023 | IND‑enabling studies completed; GLP toxicology showed no observable adverse effect level (NOAEL) at 100 mg kg⁻¹ day⁻¹ in rats. | CRO contract (Charles River Labs) | | 2024 | Phase I clinical trial (single‑ascending dose) initiated in healthy volunteers (N = 48). Primary safety endpoints met; pharmacokinetic profile favorable (t₁/₂ ≈ 8 h, oral bioavailability ≈ 62 %). | Clinical research unit, Boston, MA |

The term "Juq 395" was first spotted on online forums and discussion boards, where users began to speculate about its meaning and significance. Some believed it to be a cryptographic code or a reference to a specific piece of software, while others thought it might be a nickname or an abbreviation for a particular concept or idea. Despite the numerous attempts to decipher its meaning, the origin and purpose of "Juq 395" remain unclear, fueling the mystery and intrigue surrounding the phrase. juq 395

Word count: ≈ 1 300

Note : The name “Juq‑395” derives from the internal project code (“Juq” = JuqBio) and the hit number (#395) from the original screen. The compound is currently in Phase IIa (dose‑ranging efficacy study) as of early 2026. | Year | Milestone | Key Players |